Please assess the completion status of the following clinical trial:

Trial Title: Humoral Immunodeficiency in CLL and Therapy With Subcutaneous Ig

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of chronic lymphocytic leukemia~* Medically stable, with expected survival of \> 1 year~* Able to understand and willingness to sign a written informed consent~* Able to comply with study procedures~Exclusion Criteria:~* Previously diagnosed primary immunodeficiency~* Additional immunosuppressive states as assessed by the primary or co investigators~* Ongoing therapy with Ig replacement~* Serum IgG \< 500 mg/dL

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ig replacement (Type: EXPERIMENTAL): Subjects will receive Hizentra 0.4 mg/kg subq once weekly.

Based on this trial design, predict the completion outcome and termination type (if applicable).